Cytosorbents Co. (NASDAQ:CTSO) Short Interest Down 5.7% in September

Cytosorbents Co. (NASDAQ:CTSO - Get Free Report) saw a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 1,330,000 shares, a decline of 5.7% from the September 15th total of 1,410,000 shares. Based on an average daily volume of 91,700 shares, the short-interest ratio is presently 14.5 days.

Hedge Funds Weigh In On Cytosorbents

Large investors have recently added to or reduced their stakes in the stock. Key Client Fiduciary Advisors LLC raised its position in Cytosorbents by 188.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company's stock worth $33,000 after acquiring an additional 22,557 shares during the period. Atomi Financial Group Inc. acquired a new position in Cytosorbents during the third quarter worth $51,000. CM Management LLC raised its position in shares of Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company's stock valued at $598,000 after buying an additional 25,000 shares during the last quarter. Sargent Investment Group LLC raised its position in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company's stock valued at $1,008,000 after buying an additional 67,181 shares during the last quarter. Finally, Avenir Corp raised its position in shares of Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company's stock valued at $3,014,000 after buying an additional 121,294 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Stock Performance

NASDAQ CTSO traded up $0.03 during mid-day trading on Wednesday, reaching $1.12. 31,438 shares of the stock were exchanged, compared to its average volume of 122,759. The business's 50 day moving average is $1.14 and its 200-day moving average is $0.99. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $2.15. The company has a market capitalization of $60.82 million, a P/E ratio of -1.85 and a beta of 0.51. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.71 and a current ratio of 2.12.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The company had revenue of $9.89 million during the quarter, compared to analysts' expectations of $9.73 million. Cytosorbents had a negative net margin of 68.70% and a negative return on equity of 131.84%. During the same period in the prior year, the business posted ($0.14) earnings per share. On average, equities research analysts forecast that Cytosorbents will post -0.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on CTSO shares. HC Wainwright reissued a "neutral" rating and set a $1.00 target price on shares of Cytosorbents in a research report on Wednesday, August 14th. StockNews.com assumed coverage on shares of Cytosorbents in a report on Wednesday, October 9th. They issued a "hold" rating on the stock. Finally, EF Hutton Acquisition Co. I raised shares of Cytosorbents to a "strong-buy" rating in a report on Monday, July 29th.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.